TETRA BIO-PHARMA VOLUNTEERS TO GUIDE
MEDICAL DEVICE/ HEALTH-RELATED MANUFACTURERS
OTTAWA, April 8, 2020 /CNW/ - Tetra Bio-Pharma Inc.
("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in
cannabinoid-derived drug discovery and development has joined the
battle to fight the novel COVID-19 virus. The Company will mobilize
its expertise in regulatory affairs and quality assurance to
support Canadian businesses seeking Health Canada approval for
specific products used to mitigate the ongoing COVID-19
pandemic.
This week Tetra Bio-Pharma submitted a Drug Information Number
(DIN) application to Health Canada on behalf of a Canadian company
ready to produce a hospital, institutional grade hard surface
disinfectant. Tetra provided its intellectual know-how on a
pro-bono basis. These regulatory services would typically cost
companies thousands of dollars using a third-party service
provider. Equally important are the efficiencies and time savings
realized, which could mean a faster delivery of goods that are in
tremendous demand.
"COVID-19 is unprecedented in our lifetime and calls for an
unprecedented response from all of us," says Tetra Bio-Pharma CEO
and CRO, Dr. Guy Chamberland.
Our staff of more than 30 experts in the fields of medical
devices and drugs have decades of experience and regulatory
knowledge in preparing and filing applications to regulators like
Health Canada and FDA. Tetra also enjoys numerous years of
experience in Quality Assurance (QA) with a team experienced in
international requirements for drugs and medical devices. Helping
these entrepreneurs secure approvals and avoid unnecessary delays
in doing so may help save lives, which is why we support these
efforts at 100 percent. Needless to say, this goes beyond our
normal daily routine, our top priorities remain the
SERENITY©, PLENITUDE© and HCC-011
projects".
"We are committed to doing whatever we can to help flatten the
curve of this life-threating virus." said Tetra's President
Sylvain Chrétien. "The Tetra team is
used to going above and beyond the call of duty and our QA and
regulatory affairs colleagues have the ability to provide the kind
of insights that could bring these vital products to the frontline
faster. Tetra is pleased to be able to use its internal resources
to provide these services without the Company incurring additional
expenses.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a
biopharmaceutical leader in cannabinoid-based drug discovery and
development with a Health Canada approved, and FDA reviewed and
approved, clinical program aimed at bringing novel prescription
drugs and treatments to patients and their healthcare providers.
The Company has several subsidiaries engaged in the development of
an advanced and growing pipeline of Bio Pharmaceuticals, Natural
Health and Veterinary Products containing cannabis and other
medicinal plant-based elements. With patients at the core of what
we do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing
bio pharma industry by regulators, physicians and insurance
companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of this
product or any other product, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
SOURCE Tetra Bio-Pharma